Comparing the effectiveness of pregabalin and duloxetine in the management of neuropathic pain
DOI:
https://doi.org/10.15218/zjms.2025.020Keywords:
Pregabalin, Duloxetine, Neuropathic pain, Effectiveness, Prospective studyAbstract
Background and objective: Neuropathic pain is a type of pain that originates from damage or dysfunction of the somatosensory nervous system. Managing neuropathic pain is a challenging task as it is chronic and has limited treatment options. Pregabalin and duloxetine aim to alleviate neuropathic pain symptoms and enhance quality of life for patients. The comparative effectiveness of these drugs, particularly at lower doses that are typically provided in the Kurdistan Region of Iraq, is still a topic of inquiry that is presently being carried out. The objective of the study is to evaluate and compare the effectiveness of pregabalin and duloxetine on pain management and sleep quality in patients with neuropathic pain. Such insights are crucial for optimizing neuropathic pain management strategies and improving patient outcomes.
Methods: in this prospective study, 80 patients displaying signs and symptoms of neuropathic pain such as sharp, stabbing, numbness, and/or burning pain as well as tingling, loss of balance and coordination, and/or muscle weakness, especially in the feet were prescribed either pregabalin (n=40) or duloxetine (n=40) with mean doses of 82.5± 5.16 mg/day and 34.5± 2.46 mg/day, respectively, administered once or twice daily for 4 weeks. The results were based on the effectiveness of the drugs in reducing visual analogue scale and pain related sleep interference scale scores.
Results: Both pregabalin and duloxetine reduced the signs and symptoms of neuropathic pain, demonstrating similar efficacy within the first 3 weeks of the treatment. However, by the 4th week, duloxetine exhibited superior effectiveness in managing neuropathic pain (P = 0.001). On the other hand, findings showed no significant difference in the reduction of sleep scores (P = 0.978).
Conclusion: Both pregabalin and duloxetine are similarly effective in managing neuropathic pain during the first 3 weeks of treatment. However, when the treatment duration extends beyond 3 weeks, duloxetine demonstrates superior effectiveness in reducing neuropathic symptoms.
Metrics
References
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nature Reviews Disease Primers. 2017; 3(1):1-9. DOI: 10.1038/nrdp.2017.2
Whittlesea C, Hodson K, editors. Clinical Pharmacy and Therapeutics E-Book: Clinical Pharmacy and Therapeutics E-Book. Elsevier Health Sciences; 2018; 1(1).
Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact, and risk factors. Pain. 2020; 161:S127-37. DOI: 10.1097/j.pain.0000000000001824
Gylfadottir SS, Christensen DH, Nicolaisen SK, Andersen H, Callaghan BC, Itani M, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain. 2020; 161(3):574-83. DOI: 10.1097/j.pain.0000000000001744
Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. The Clinical journal of pain. 2007; 23(2):143-9. DOI: 10.1097/01.ajp.0000210956.31997.89
Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010; 149(2):338-44. DOI: 10.1016/j.pain.2010.02.034
- Al-Shammaa ZM, Aladul MI, Essa NS. Trends in anti-neuropathic medications turnover in Iraq. JPSHR. 2023; 14(4):407-14. DOI: doi.org/10.1093/jphsr/rmad042
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2):162-73. DOI: 10.1016/S1474-4422(14)70251-0
2004a. Drug Approval Letter: Cymbalta (Duloxetine Hydrochloride) Delayed Release Tablets[Online]. Available on: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021733s000_Cymbalta_approv.pdf [Accessed 2024].
2004b. Drug Approval Letter: Lyrica (Pregabalin) Capsules [Online]. Available on : https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_Lyrica%20Capsules_approv.PDF [Accessed 2024].
Bitter I, Filipovits D, Czobor P. Adverse reactions to duloxetine in depression. Expert opinion on drug safety. 2011; 10(6):839-50. DOI: 10.1517/14740338.2011.582037
Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nature Reviews Drug Discovery. 2013; 12(2):103-15. DOI: 10.1038/nrd3931
Agyeman AA, Ofori-Asenso R. Perspective: Does personalized medicine hold the future for medicine?. Journal of Pharmacy and Bioallied Sciences. 2015; 7(3):239-44. DOI: 10.4103/0975-7406.160040
Scott J, Huskisson EC. Graphic representation of pain. Pain. 1976; 2(2):175-84. DOI: 10.1097/01.NHH.0000281614.96670.80.
Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology. 2009; 9:1-4.DOI: 10.1186/1471-2377-9-6
Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V, Malcolm SK. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011; 86(17):615-626. DOI: 10.4065/mcp.2010.0681
Joharchi K, Memari M, Azargashb E, Saadat N. Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. Journal of Diabetes & Metabolic Disorders. 2019; 18:575-82. DOI:10.1007/s40200-019-00427-w
Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. International Journal of Neuropsychopharmacology. 2013; 16(4):925-36. DOI:10.1017/S1461145712000922
Roth T, Arnold LM, Garcia-Borreguero D, Resnick M, Clair AG. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Medicine Reviews. 2014; (3):261-71. DOI: 10.1016/j.smrv.2013.07.005
Tan L, Zhou J, Yang L, Ren R, Zhang Y, Li T, Tang X. Duloxetine-induced rapid eye movement sleep behavior disorder: a case report. BMC psychiatry 2017; 17:1-5. DOI: 10.1186/s12888-017-1535-4
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials. Epilepsia. 2011; 52(4):826-36. DOI: 10.1111/j.1528-1167.2010.02966.x
Zilliox LA. Neuropathic pain. Continuum (Minneap Minn). 2017; 23(2):512-32. DOI: 10.1212/CON.0000000000000462
Rodrigues AD, Olivares JM, Spuch C, Rivera BT. A systematic review of efficacy, safety, and tolerability of duloxetine. Frontiers in psychiatry. 2020; 11:554899. DOI: 10.3389/fpsyt.2020.554899
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rojgar Hamed Ali, Govand Shafeeq Tawfeeq, Amanj Mohsin Mustafa, Shayma Abdulmanaf Shakir, Najat Ghanim Salem, Aswan Idrees Swedi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
